DecisionDx®-SCC Scientific References
Ibrahim S, Kasprzak J, Hall M et al. Enhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile test. Future Oncology 2021. doi: https://www.futuremedicine.com/doi/10.2217/fon-2021-1277
Wysong, A, Newman J, Covington K et al. Validation of a 40-gene expression profile test to predict metastatic risk in localized high-risk cutaneous squamous cell carcinoma. JAAD 2021; 361-368. doi: https://www.jaad.org/article/S0190-9622(20)30704-0/fulltext
Arron S, Wysong A, Hall M, et al. Gene expression profiling for metastatic risk in head and neck cutaneous squamous cell carcinoma. Laryng Investig Oto 2022; 1-10. doi: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8823155/
Borman S, Wilkinson J, Meldi-Sholl L et al. Analytical validity of DecisionDx-SCC, a gene expression profile test to identify risk of metastasis in cutaneous squamous cell carcinoma (SCC) patients. Diagnostic Pathology 2022. doi: https://diagnosticpathology.biomedcentral.com/articles/10.1186/s13000-022-01211-w
Farberg A, Fitzgerald A, Ibrahim S et al. Current Methods and Caveats to Risk Factor Assessment in Cutaneous Squamous Cell Carcinoma (cSCC): A Narrative Review. Dermatol Ther 2022. doi: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850485/
Au J, Hooper P, Somani AK et al. Clinical Utility of the 40-Gene Expression Profile (40-GEP) Test for Improved Patient Management Decisions and Disease-Related Outcomes when Combined with Current Clinicopathological Risk Factors for Cutaneous Squamous Cell Carcinoma (cSCC): Case Series. Dermatol Ther 2021. doi: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850491/
Arron S, Blalock T, Guenther M, et al. Clinical considerations for integrating gene expression profiling into cutaneous squamous cell carcinoma management. JDD 2021; s5-s10. doi: https://jddonline.com/articles/clinical-considerations-for-integrating-gene-expression-profiling-into-cutaneous-squamous-cell-carci-S1545961621S005sX/
Farberg AS, Hall MA, Douglas L, et al. Integrating gene expression profiling into NCCN high-risk cutaneous squamous cell carcinoma management recommendations: Impact on patient management. Curr Med Res Opin 2020. doi:10.1080/03007995.2020.1763284.
Litchman GH, Fitzgerald AL, Kurley SJ, et al. Impact of a prognostic 40-gene expression profiling test on clinical management decisions for high-risk cutaneous squamous cell carcinoma. Curr Med Res Opin 2020. doi:10.1080/03007995.2020.1763283.
Teplitz R, Prado G, Litchman GB, Rigel DS. Impact of gene expression profile testing on the management of squamous cell carcinoma by dermatologists. J Drugs Dermatol 2019;18:980-4.
National Comprehensive Cancer Network. Squamous Cell Skin Cancer, NCCN Guidelines Version 1.2020.
Likhacheva A, Awan M, Barker CA, et al. Definitive and postoperative radiation therapy for basal and squamous cell cancers of the skin: Executive summary of an American Society for Radiation Oncology clinical practice guideline. Pract Radiat Oncol 2020;10:8-20.
Alam M, Armstrong A, Baum C, et al. Guidelines of care for the management of cutaneous squamous cell carcinoma. J Am Acad Dermatol 2018;78:560-78.
Karia PS, Jambusaria-Pahlajani A, Harrington DP, et al. Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women’s Hospital tumor staging for cutaneous squamous cell carcinoma. J Clin Oncol 2014;32:327-34.
Connolly SM, Baker DR, Coldiron BM, et al. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: A report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery. J Am Acad Dermatol 2012;67:531-50.